期刊文献+

沙格列汀联合二甲双胍治疗2型糖尿病40例的疗效及安全性 被引量:5

下载PDF
导出
摘要 目的:总结分析沙格列汀联合二甲双胍在2型耱尿病患者治疗中的应用效果和安全性。方法:选择2012年6-11月期间我院收治的80例2型糖尿病患者为研究时象,随机分为观察组和对照组各40例,对照组患者给予二甲双胍治疗,观察组患者给予沙格列汀联合二甲双胍治疗。治疗1个月后比较两组患者血糖、HbAlc(糖化血红蛋白)、不良事件等。结果:经过1个月治疗后观察组患者FBG、2hPG、HbAlc均明显低于时照组。差异均具有统计学意义(P〈0.01);两组患者在药物治疗期间均未发生低血糖事件.其中观察组4例出现胃肠道反应,对照组2倒出现胃肠道反应,差异无统计学意义。结论:沙格列汀联合二甲双胍治疗2型糖尿病能良好控制血糖。用药安全.值得临床推广。
作者 禤德医
出处 《实用中西医结合临床》 2014年第5期18-19,共2页 Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献7

二级参考文献31

  • 1周琼,欧阳金芝,张木勋,张建华,杨雁.胰升糖素样肽-1对高游离脂肪酸诱导的胰岛β细胞凋亡作用的研究[J].临床内科杂志,2007,24(4):275-277. 被引量:2
  • 2Aschner P,Kipnes MS, Lunceford JK,et al. Effect of the dipeptidylpeptidase-finhibitor sitg^lipt-in as monotherapy on glycemic controlin patients woth type 2 diabetes. Diabetes Care, 2006,29 ( 12 ):2632-2637.
  • 3Raz I,Chen Y,Wu M, et al. Efficacy and safety of sitagliptin addedto ongoing metformin therapy in patients with type 2 diabetes. CurrMed Hes Opin,2008,24(2) :537-550.
  • 4Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sita-gliptin monotherapy in Japanese patients with type 2diabetes. Dia-betes Res Clin Pract,2008,79(2) :291-298.
  • 5Hermansen K, Kipnes M,Luo E, et al. Efficacy and safety of thedipeptidyl peptidase-4 inhibitor,sitagliptin,in patients with type 2diabetes mellitus inadequately controlled on glimepiride alone or onglimepiride and metformin. Diabetes Obes Metab,2007,9 (5):733-745.
  • 6Drucker DJ,Nauck MA. The incretin system:glucagonlike peptide-1 re- ceptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet,2006,368 : 1696-1705.
  • 7Salehi M, Aulinger BA, D'Alessio DA. Targeting 13-cell mass in type 2 diabetes:promise and limetations of new drugs based on incretins. En- doer Rev ,2008,29:367-379.
  • 8Mannucci E,Tesi F,Bardini G,et al. Effects of mefformin on glucagon- like peptide-1 levels in obese patients with and without Type 2 diabe- tes. Diabetes Nutr Metab,2004,17:336-342.
  • 9Yasuda N, Inoue T, Nagakura T, et al. Enhanced secretion of glucagon- like peptide 1 by biguanide compounds. Bioehem Biophys Res Com- mun ,2002,298:779-784.
  • 10Knop FK. Reduced incretin effect in type 2 diabetes:cause or conse- quence of the diabetic state? Diabetes,2007,56:1951-1959.

共引文献151

同被引文献40

  • 1宋燕庆.二甲双胍联合沙格列汀与二甲双胍单药治疗2型糖尿病疗效比较[J].兵团医学,2013(4):18-19. 被引量:2
  • 2Barnett AH,Charbonnel B,Moses RG,et al.Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus[J].Curr Med Res Opin,2015;31(10):1919-31.
  • 3Scirica BM,Braunwald E,Raz I,et al.Heart failure,saxagliptin,and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized tria[J].Circulation,2015;132(6):e120.
  • 4Matthaei S,Catrinoiu D,Celiński A,et al.Randomized,double-blind tria of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes[J].Diabetes Care,2015;38(11):2018-24.
  • 5DeF ronzo RA,Hissa MN,Garber AJ,et al.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inad-equately controlled type 2 diabetes with metformin alone[J].Diabetes Care,2009;32(9):1649-55.
  • 6Jadzinsky M,Pfutzner A,Paz-Pacheco E,et al.Saxagliptin given in combination with metformin as initial therapy improves glycae-mic control in patients with type 2 diabetes compared with either monotherapy:A randomized controlled tria[lJ].Diabet Obes Metab,2009;11(6):611-22.
  • 7Yang W,Pan CY,Tou C,et al.Efficacy and safety saxagliptin added to metformin in Asian people with type 2 diabetes melitus:a randomized contrrolled tria[lJ].Diabet Res Clin Pract,2011;94(2):217-24.
  • 8Mosenzon O,Wei C,Davidson J,et al.Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial[J].Diabetes Care,2015;38(11):2142-50.
  • 9Pech V,Abusaada K,Alemany C.Dipeptidyl peptidase-4 inhibition may stimulate progression of carcinoid tumor[J].Case Rep Endocrinol,2015;2015(1):952019.
  • 10Mathieu C,Ranetti AE,Li D,et al.Randomized,double-blind,phase 3trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes[J].Diabetes Care,2015;38(11):2009-17.

引证文献5

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部